Kapa3 on European Carers Day: Supporting Carers Is an Essential Part of Supporting Patients

The often unseen burden on families, evidence from Kapa3’s everyday practice, and the need for patient navigation, psychosocial support and equitable access to cancer care.

Athens, 6 October 2026

Kapa3 – Cancer Guidance Centre participated in an event organised by the Greek Carers Network EPIONI to mark European Carers Day, held on Tuesday, 6 October 2026, at the European Parliament Liaison Office in Greece, Athens.

In their presentation entitled “The Caregiver as a Key Pillar of Support for Cancer Patients: The Greek Reality,”Evangeli Bista, Co-founder of Kapa3, and Marilia Barka, Psychology student and Kapa3 volunteer, highlighted the multifaceted role of informal carers, the challenges they face and the importance of recognising their contribution to cancer care.

The presentation brought together scientific knowledge and practice-based evidence from Kapa3’s daily operations, highlighting the fact that effective support for people affected by cancer must extend beyond medical treatment.

Cancer care does not end at the hospital. It continues at home, at work, within the family and throughout everyday life.

Informal Carers: The Invisible Coordinators of Cancer Care

Behind many cancer journeys is someone who coordinates appointments, searches for reliable information, manages administrative procedures, organises transportation and provides emotional support.

Informal carers, often family members or people from the patient’s immediate social environment, frequently become the invisible coordinators of care.

Their contribution, however, comes with significant practical, social, financial and psychological demands.

Balancing employment with caregiving responsibilities, losing personal time, facing additional expenses and coping with uncertainty about the course of the disease can substantially affect carers’ quality of life.

These challenges do not necessarily disappear when treatment ends.

Recovery, rehabilitation, returning to everyday routines and adapting to changing family roles may create additional responsibilities and emotional pressures.

Supporting carers is not simply an additional social service. It is an essential component of continuity and quality of care.

What Kapa3’s Data Reveal

Kapa3’s everyday experience demonstrates the important role carers play in seeking information and support.

According to the organisation’s internal telephone activity records, 1,251 telephone contacts were recorded between 27 January and 30 July 2026.

These included 614 incoming and 637 outgoing contacts, with 184 incoming contacts initiated by carers.

In addition, Kapa3’s service records for 2024–2025 indicate that 50.7% of first contacts were initiated by carers. Within the corresponding records, 89.1% of carers who contacted the organisation were first-degree relatives.

These figures describe activity recorded within Kapa3’s services. They should not be interpreted as nationally representative statistics on informal caregiving in Greece.

Nevertheless, they highlight an important reality: the first person seeking guidance is often not the patient, but someone supporting them.

Common requests concern administrative guidance, social rights and benefits, disability certification procedures, employment-related support and access to psychological services.

The challenge is not always a lack of information.

Information is often fragmented across multiple institutions, subject to changing procedures and difficult to translate into practical next steps.

Patients and carers need more than information. They need reliable guidance that helps them take action.

The Psychological Burden of Caregiving Is Not Always Visible

Caregiver burden extends well beyond physical fatigue.

It may involve psychological distress, financial insecurity, changing family dynamics, social isolation and profound existential concerns.

Carers are often expected to remain available and resilient even while experiencing fear, sadness, uncertainty or exhaustion themselves.

Some may hesitate to express their needs, believing that all attention should remain focused on the person living with cancer.

Recognising caregiver distress and ensuring access to psychosocial care, counselling and practical assistance are therefore essential elements of comprehensive cancer support.

Caring for carers is part of caring for patients.

Patient Navigation: Connecting Needs with Support

At Kapa3, patient and social navigation involves much more than answering individual questions.

It is a structured process of identifying needs, recording and prioritising requests, exploring solutions, referring people to appropriate services and reviewing the support provided.

This approach seeks to connect patients and carers with healthcare services, social protection systems and relevant professionals.

Social work and interdisciplinary collaboration are particularly important in addressing practical, financial, administrative and psychological needs in a coordinated way.

Kapa3’s experience highlights that meaningful access to care depends not only on the availability of services, but also on people’s ability to understand, reach and effectively use them.

MYRTO: Digital Innovation Strengthening Human Guidance

The presentation also introduced MYRTO – Kapa3’s AI-Supported Digital Social Navigator, designed to facilitate access to evidence-informed information on social rights, benefits and support services.

MYRTO is being developed in technological collaboration with SimasiaAI, with the valuable support of the TIMA Charitable Foundation.

Using documented information sources, plain language and clarifying questions, the application aims to make complex information easier to access and understand.

Human oversight and referral to appropriate support professionals remain essential aspects of its approach.

According to an administrative dashboard snapshot dated 19 September 2026, MYRTO had recorded 2,220 sessions. This figure refers to application sessions, not necessarily to unique users or beneficiaries.

Topics raised through the application included healthcare benefits, medicines and treatment, disability certification, patient and caregiver rights, employment matters and social protection.

At Kapa3, the value of Artificial Intelligence lies in its ability to strengthen human support rather than replace it.

Technology can organise information. Human relationships make care possible.

Employment and Caregiving: The Need for Institutional Recognition

Supporting someone with cancer frequently affects carers’ professional lives.

Attending appointments, responding to unexpected needs and managing everyday responsibilities require time, flexibility and appropriate employment arrangements.

Accessible information on existing rights and leave entitlements, flexible working arrangements where applicable, return-to-work support and greater awareness among employers and human resources departments can help reduce the burden.

Recognising caregiving responsibilities and preventing workplace exclusion should be part of a broader approach to social protection and inclusive employment.

Five Priorities for More Equitable Cancer Care

Kapa3’s presentation outlined five priorities:

  1. Recognition of informal carers as essential partners in care and social policy.
  2. Integration of patient navigation as a consistent component of organised cancer care.
  3. Access to psychosocial support from diagnosis and throughout the cancer journey.
  4. Responsible digital inclusion, based on plain language, accessibility, transparency and human oversight.
  5. Collaboration and sustainable funding, involving public authorities, local government, healthcare professionals and civil society organisations.

These priorities reflect the need for a healthcare and social support system that recognises the interconnected needs of patients, survivors and carers.

From Recognition to Meaningful Support

Kapa3’s participation in the event organised by EPIONI provided another opportunity to highlight the needs of people who provide care every day, often without sufficient recognition or structured support.

Carers’ lived experiences, systematically documented service needs and scientific evidence can inform more responsive healthcare services and public policies.

For Kapa3, care must be understood as an ongoing process connecting people with reliable information, appropriate services, professionals and their communities.

No cancer journey without navigation.

No digital innovation without human connection.

Because care concerns not only the person living with cancer, but also those standing beside them.


Event Information

European Carers Day 2026

Date: 6 October 2026
Venue: European Parliament Liaison Office in Greece, 8 Vasilissis Amalias Avenue, Athens
Organiser: Greek Carers Network EPIONI

Event information:
https://epioni.gr/εκδήλωση-για-την-ευρωπαϊκή-ημέρα-φρον/

Kapa3 – Cancer Guidance Centre
https://www.kapa3.gr/

Explore MYRTO – Digital Social Navigator
https://kapa3-cag-rag-hybrid-deploy.onrender.com/

Online Webinar Digital Transformation in the Public Sector and Civil Society.Convergence or divergence and proposals

Kapa3 – Cancer Guidance Centre, in collaboration with Collège René Descartes, invites you to an online webinar entitled:

“Digital Transformation in the Public Sector and Civil Society: Convergence or divergence and proposals”

📅 Date: Friday, 30 October 2026
🕡 Time: 18:30 – 20:30
💻 Attendance: Online
🎫 Participation: Free of charge

Digital transformation is now a key factor shaping how public organisations operate, how services are delivered to citizens, and how social support and participation initiatives are developed. Although important progress has been made, the transition to a more digital environment does not unfold in the same way across all organisations and social groups.

This webinar aims to open a meaningful dialogue between theory and practice, examining digital transformation from both the perspective of the Public Sector and that of Civil Society. Special emphasis will be placed on:

  • the changes brought by digitalisation in the way organisations function,
  • the relationship between the state, organisations and citizens,
  • the opportunities created by digital technologies,
  • the challenges arising from unequal access to and use of digital tools,
  • and the need to develop sustainable, human-centred and inclusive digital solutions.

Main question of the discussion

Does digital transformation lead to greater convergence between the state, organisations and citizens, or does it create new forms of divergence and inequality?

Who should attend

The webinar is addressed to:

  • public sector professionals and employees,
  • representatives of civil society organisations,
  • professionals involved in the design or implementation of digital services,
  • management and human resources professionals,
  • social and humanitarian service professionals,
  • educators, researchers, academics and students,
  • and, more broadly, anyone interested in the relationship between technology, public administration and society.

Main topics

The webinar programme includes themes related to:

  • digital transformation as organisational change,
  • innovation in public administration,
  • practical experiences and good practices from the public sector,
  • inclusion, accessibility and social needs,
  • the relationship between the public sector and civil society,
  • artificial intelligence, data and new opportunities,
  • and proposals for a meaningful, sustainable and human-centred digital transition.

Speakers

The webinar features:

  • Anastasia Tsartara, Head of Sector “Internal Affairs, Digital Governance, Justice and Institutions”, General Secretariat for Coordination of the Presidency of the Government
  • Dr Emmanuel Alexandrakis, Adjunct Professor – Strategic Development and Internationalisation Advisor, Athens University of Economics & Business
  • Evangeli Bista, Cofounder / Strategic Partnerships Lead, Kapa3 – Cancer Guidance Centre
  • Eirini Gkoni, Associate, GRNET S.A.
  • Dimitris Papadakis, Co-Founder & Head of Sales, SimasiaAI
  • Aristea Archontidou, MSc in Health Policy & Planning, Kapa3 Associate.

Certificate of attendance

All participants will receive a certificate of attendance issued by Collège René Descartes and Kapa3.

Registration

Participation is free. You may register through the official form:
🔗 https://cnam.gr/webinar_digital_transformation_public_management/

Beyond Treatment: What Project 528 Reveals About Young Women Living with Advanced Breast Cancer

The hidden burden of diagnosis, the need for holistic care, and Kapa3’s commitment to patient navigation, psychosocial support and empowerment.

A cancer diagnosis at a young age affects far more than physical health. It can disrupt education, employment, family life, personal relationships, financial security and plans for the future. For young women living with advanced breast cancer, these challenges are often particularly complex, as they must navigate treatment and uncertainty while continuing to fulfil multiple personal, professional and family responsibilities.

The findings of Project 528, a global needs assessment led by the Young Survival Coalition (YSC), provide important evidence of these often-overlooked realities.

Presented at the 8th International Consensus Conference for Advanced Breast Cancer (ABC8) in Lisbon in November 2025, the survey gathered 3,881 responses from 67 countries. The findings presented at the conference focused on 385 young respondents under the age of 40 living with advanced breast cancer.

The results highlight significant gaps in access to information, psychological support, financial protection, practical assistance and meaningful participation in healthcare decisions.

Above all, they reinforce an essential message: cancer care must address the whole person, not only the disease.

The revealing findings of Project 528

The survey findings offer a compelling picture of the challenges experienced by young women with advanced breast cancer and demonstrate how deeply the disease affects everyday life.

Motherhood and family responsibilities

Almost half of the respondents (48%) had children under the age of 18.

For young mothers, living with advanced breast cancer means balancing demanding treatment schedules, physical symptoms and emotional uncertainty with the everyday responsibilities of raising children.

Childcare, family routines and concerns about their children’s future can become considerable sources of distress.

These findings highlight the importance of family-centred supportive care that recognises both the needs of patients and those of their loved ones.

Employment disruption and financial toxicity

The socioeconomic consequences of advanced breast cancer are substantial.

64% of respondents reported disruption to their employment following diagnosis, while 40% accumulated medical debt.

According to the detailed Project 528 report, the proportion of respondents who considered themselves financially secure fell from 51% before diagnosis to just 7% during treatment.

These findings illustrate the phenomenon of financial toxicity: the economic burden associated with cancer, including loss of income, treatment-related expenditure, travel costs, caregiving responsibilities and reduced employment opportunities.

Financial insecurity can further intensify emotional distress and create additional barriers to accessing appropriate care.

For younger patients, whose careers and financial independence may still be developing, the consequences can extend well beyond the treatment period.

Psychological distress and quality of life

80% of respondents reported psychological distress or mental health difficulties.

Concerns relating to body image, fertility, sexual health, emotional well-being and loss of independence were widespread, yet were often insufficiently addressed within routine cancer care.

For many young women, advanced breast cancer also raises difficult questions about identity, relationships, intimacy, motherhood and the future.

These challenges demonstrate why psychosocial support should not be viewed as an optional addition to cancer treatment.

It is an essential component of comprehensive, person-centred oncology care.

Delays in seeking care and diagnosis

The survey also revealed important gaps in awareness and early detection.

40% of respondents reported delaying their initial medical consultation. Contributing factors included fear, limited awareness of symptoms and experiences of having their concerns dismissed or underestimated by healthcare professionals.

Only 14% reported being diagnosed through screening or routine medical care, while 85% sought diagnosis after identifying symptoms themselves.

These findings point to the need for greater awareness of breast cancer in younger populations, timely clinical assessment of concerning symptoms and improved communication between patients and healthcare professionals.

They also remind us that young age should not automatically lead to the dismissal of potentially significant symptoms.

Gaps in information and access to precision medicine

The findings also identified differences in access to diagnostic testing and understanding of treatment options.

Although 90% reported undergoing genetic testing for inherited mutations, only 59% had received genomic or companion diagnostic testing to investigate characteristics of the tumour.

Such testing, when clinically indicated, can provide valuable information to support personalised treatment decisions.

Moreover, only 46% of respondents reported being offered more than one treatment option, while targeted therapies were among the least understood treatment approaches.

These results highlight the importance of accessible medical information, effective patient–professional communication and shared decision-making.

Online patient communities also emerged as valuable sources of information, peer support and empowerment. However, the detailed Project 528 report found that 43% had not been referred to peer-support or patient advocacy groups by their healthcare teams.

As Jennifer Merschdorf, Chief Executive Officer of the Young Survival Coalition, emphasised, healthcare systems too often place the burden of self-advocacy on patients who are already coping with fatigue, fear and financial strain.

The Kapa3 connection: From identifying needs to meaningful action

The findings of Project 528 are more than statistics. They reveal the personal, social and economic dimensions of cancer that healthcare systems must increasingly recognise and address.

Although the survey reflects experiences reported across different countries and healthcare contexts, many of the challenges it identifies are also relevant to the needs that cancer patients and families may encounter in Greece.

At Kapa3 – Cancer Guidance Center, we believe that the experience of cancer extends far beyond hospital appointments, medical consultations and treatment decisions.

Cancer affects the ability to work, care for loved ones, maintain financial stability, access essential services and participate fully in everyday life.

Our mission is to help bridge the gap between medical care and the practical, social and emotional needs that accompany a cancer diagnosis.

Patient navigation and guidance within healthcare and social support systems

As Professor Fatima Cardoso, President of the ABC Global Alliance, has highlighted, equitable access to appropriate diagnostics, personalised treatment and comprehensive supportive care is essential.

At Kapa3, we provide free patient navigation and social guidance services, helping people affected by cancer and their families better understand their rights and access available forms of support.

Our work includes guidance on administrative procedures, disability assessment and certification, social benefits, insurance-related matters, workplace rights and available community resources.

Through individualised support and cooperation with relevant services, we aim to reduce the bureaucratic and informational barriers that patients frequently encounter.

No person affected by cancer should have to navigate a complex health and welfare system alone.

Psychosocial support and quality of life

With psychological distress affecting such a high proportion of young patients in the Project 528 survey, emotional and psychosocial care must be recognised as a central part of the cancer journey.

Kapa3 provides psychological support services adapted to the needs of patients and caregivers, alongside social guidance and referrals to appropriate specialised services when necessary.

We recognise the importance of offering a supportive environment where people can discuss emotional uncertainty, changes in family and personal relationships, body image concerns, fear of recurrence or progression, and the challenges of adapting to life with cancer.

Our approach promotes dignity, emotional resilience and a more comprehensive understanding of quality of life.

Practical assistance and support for families

For a young mother living with advanced breast cancer, routine tasks can become overwhelming.

Childcare arrangements, travel for treatment, household responsibilities, employment obligations and financial pressures may all create additional burdens.

Kapa3 supports patients and caregivers by identifying their practical needs, providing information and connecting them with appropriate social services, community resources and support structures.

Through collaboration with local authorities, healthcare professionals and community organisations, we seek to strengthen continuity of support and help families navigate everyday challenges.

Empowerment, health literacy and patient advocacy

One of the strongest messages emerging from Project 528 is that reliable information is a fundamental resource for patient empowerment.

At Kapa3, we work to strengthen health literacy, informed participation and patient advocacy.

We encourage patients to ask questions, understand the information provided by their healthcare teams, become aware of relevant diagnostic and treatment options, and participate actively in decisions affecting their lives.

Our role is not to replace medical advice, but to help people access trustworthy information and feel better prepared to communicate with healthcare professionals.

At the same time, we advocate for more inclusive health and social policies that recognise the particular challenges experienced by adolescents and young adults affected by cancer (AYAs).

These include employment protection, financial security, psychosocial needs, family responsibilities, fertility-related concerns and continuity of care.

Moving forward together: Advocating for a better quality of life

Project 528 offers an important roadmap for researchers, healthcare professionals, patient organisations and policymakers.

It demonstrates the urgent need for healthcare systems that are not only medically effective, but also accessible, coordinated, compassionate and responsive to the realities of people’s lives.

The findings should be interpreted in the context of the survey’s limitations, including its reliance on self-reported experiences and uneven geographical representation. Nevertheless, they provide valuable patient-reported evidence that can inform further research and improvements in supportive care.

Behind every diagnosis is a woman who wants to continue living, loving, working, raising her children, building relationships and making plans for the future.

As Christina Thammasen, who shared her experience of living with metastatic breast cancer, reminds us:

“You have to keep fighting, you have to keep moving forward, you have to keep living your life.”

At Kapa3, we remain committed to ensuring that no woman, no young adult and no family affected by cancer has to face these challenges without information, guidance or support.

We advocate for a model of holistic, person-centred cancer care that extends beyond treatment and recognises every dimension of human life.

Because cancer care is not only about treatment. It is about protecting dignity, supporting everyday life and ensuring that no one is left behind.


Need support?

If you are a young person affected by cancer, a patient or a caregiver seeking guidance, psychological support or information about your rights, the Kapa3 team is here to help.

Kapa3 – Cancer Guidance Center

Telephone: +30 210 5221424
Email: info@kapa3.gr
Website: www.kapa3.gr

Sources and further reading

  1. Young Survival Coalition. Project 528 – First Look ABC Data: Global Needs Assessment of Young Adults Affected by Advanced Breast Cancer (2025).
    https://project528.youngsurvival.org/wp-content/uploads/2025/11/MBC-Report-Project528_11.2025.pdf
  2. ABC Global Alliance / ecancer. First global survey highlights challenges faced by young women with advanced breast cancer. 6 November 2025.
    https://ecancer.org/en/news/27226-first-global-survey-highlights-challenges-faced-by-young-women-with-advanced-breast-cancer
  3. Oncology Central. ABC8: Global survey highlights challenges that young breast cancer patients face. 6 November 2025.
    https://www.oncology-central.com/abc8-global-survey-highlights-challenges-that-young-breast-cancer-patients-face/
  4. Project 528 – Official website and research findings.
    https://project528.youngsurvival.org/results/

Article edited by:
Elena Panopoulou, Sociologist, Kapa3 Tripoli Team
Email: elenak3team@gmail.com
LinkedIn: Elena Panopoulou

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern oncology is changing at an unprecedented pace. Immunotherapies, antibody–drug conjugates (ADCs), bispecific antibodies and new targeted therapies are creating treatment opportunities that would have been unimaginable only a few years ago.

Cancer treatment is becoming increasingly personalised and tailored to the biological and molecular characteristics of each tumour, while overall survival is being extended for many people living with cancer.

Yet alongside this remarkable scientific progress, a critical question is emerging:

What does it really mean to live longer after — or with — cancer?

A recent Nature Medicine editorial, entitled “Oncology must confront hidden side effects”, highlights precisely this challenge. While cancer drug development is advancing at remarkable speed, the approaches used to record, assess and manage long-term treatment-related toxicities — and their impact on patients’ quality of life — have not evolved at the same pace.

When a “mild” side effect becomes a major burden

Therapeutic success can create a new reality: people are living longer, but some must also manage treatment-related adverse effects for months, years or even for the rest of their lives.

An adverse event classified clinically as low-grade is not necessarily insignificant to the person experiencing it.

A persistent rash, diarrhoea, stomatitis or other symptoms may substantially affect daily functioning, psychological wellbeing and social life when they continue over long periods.

Similarly, some immune-related adverse events associated with immune checkpoint inhibitors can become chronic, persist for years or even be irreversible.

This highlights an important limitation of the Common Terminology Criteria for Adverse Events (CTCAE), which are widely used to classify and grade treatment-related adverse events.

The duration of adverse events is not adequately reflected, while functional and psychological consequences may also remain outside traditional toxicity assessment.

As a result, what may be considered “manageable” according to conventional clinical criteria can feel very different to the patient living with it every day.

Quality of life cannot be an afterthought

A second important issue is the timing of quality-of-life evidence.

In some cases, quality-of-life findings are reported considerably later than the primary results of a clinical trial, and sometimes after a new drug has already been approved.

This means that patients making treatment decisions during the early years of a new therapy may not yet have a complete picture of how it could affect their daily functioning, emotional wellbeing and overall quality of life.

At the same time, the questionnaires and tools used to assess quality of life need to evolve continuously.

And this cannot happen without the direct involvement of patients themselves.

The experiences and priorities of people receiving treatment should form part of how treatment impact is assessed, rather than being treated as information that is added later.

The example of daraxonrasib

The Nature Medicine editorial highlights the pan-RAS inhibitor daraxonrasib as a telling example. The therapy has shown important survival benefits for patients with aggressive RAS-driven advanced pancreatic cancer, a setting in which treatment options have historically been limited.

At the same time, most patients experienced acneiform rash, with diarrhoea and stomatitis also reported as lower-grade treatment-related adverse events.

Full quality-of-life data — including information on daily functioning and emotional wellbeing — were not yet available because follow-up remained relatively short.

This example illustrates a much wider issue.

If we know that a therapy can significantly extend life, but we do not yet fully understand what that life will be like, an essential part of the information is missing from the conversation between patients and their healthcare teams.

This also has direct implications for informed consent.

Whenever evidence is available, patients need information not only about response rates and survival but also about the potential short- and long-term consequences of treatment for their everyday lives.

The same treatment is not experienced in the same way by everyone

The toxicity profile of a treatment is not identical for every patient.

It may vary according to the drug’s mechanism of action, a person’s physical condition, co-existing long-term conditions, genetic background and other individual characteristics.

Particular attention is needed for populations that have historically been excluded from, or underrepresented in, clinical trials, as their experiences of treatment-related toxicity may differ.

The editorial points, for example, to sex-related differences in adverse events associated with immunotherapy and racial disparities in adverse events observed with CAR-T cell therapy.

This makes real-world data particularly important.

Clinical trials remain fundamental to establishing the safety and efficacy of new treatments. However, broader use in everyday clinical practice may reveal treatment effects that were not fully captured in the populations included in initial studies.

One example is the bispecific antibody amivantamab in lung cancer, where the full extent and severity of some skin toxicities became clearer after a broader patient population was exposed to the treatment.

Moving beyond clinical silos

This changing landscape also demands a different approach to the organisation of cancer care.

The adverse effects of modern cancer therapies do not always fit within a single organ system or medical specialty.

Traditional clinical and disciplinary silos can limit the transfer of knowledge needed to identify, monitor and manage emerging toxicities effectively.

The response therefore needs to be interdisciplinary.

Collaborative networks, updated guidance, systematic reporting, dedicated registries and effective knowledge exchange are increasingly important so that new or rare adverse effects can be recognised early and managed appropriately.

Above all, the patient voice must be heard

Perhaps the most important change concerns how we define treatment success itself.

Survival remains a fundamental goal of oncology.

But it cannot be the only one.

We also need to understand whether people can work, move, sleep, eat, participate in family and social life, maintain as much independence as possible and manage the effects of treatment on their everyday lives.

In other words, we need to know not only how much time a treatment adds to life, but also what that time means to the person living it.

Patients should therefore not enter the process only at the end, as recipients of treatment.

Their perspectives need to be incorporated from the design of clinical trials and assessment tools through to post-approval monitoring and the real-world use of new cancer therapies.

From survival to living after — and with — cancer

Progress in oncology is undeniable, and it brings genuine hope.

The next challenge is to ensure that longer survival is accompanied by quality of life, functioning, meaningful information, participation and dignity.

Modern cancer care therefore needs to move beyond asking only:

“How much longer can this patient live?”

and give equal importance to another question:

“How will this person live during that additional time?”

For Kapa3, this discussion goes to the heart of truly person-centred cancer care: care that sees not only the disease and the treatment, but the person, their everyday life, their needs, their choices and the life that continues during and after cancer.

Source and references

Main source:
Nature Medicine. “Oncology must confront hidden side effects.” Volume 32, July 2026. Published online 8 July 2026. DOI: 10.1038/s41591-026-04554-9.

  1. Barron CC et al. Journal for ImmunoTherapy of Cancer. 2023;11.
  2. Gyawali B et al. Lancet Oncology. 2025;26–e89.
  3. O’Reilly EM et al. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2605555.
  4. Unger JM et al. Journal of Clinical Oncology. 2022;40:1474–1486.
  5. Rayapureddy AK et al. Journal of Clinical Oncology. 2026;44.
  6. Hines MR et al. Transplantation and Cellular Therapy. 2023;29:438.e1–438.e16.

find more s41591-026-04554-9

Κapa3 at IEEE CBMS 2026 | AI for Equitable Oncology Information

Kapa3 at IEEE CBMS 2026: Artificial Intelligence in Support of Equitable Patient Information in Oncology Care

New scientific publication in the Proceedings of the 39th IEEE International Symposium on Computer-Based Medical Systems

The voice and lived experience of patients must remain at the centre of the emerging era of Artificial Intelligence in healthcare.

Kapa3 – Cancer Guidance Centre contributes to a new scientific publication presented in the Proceedings of the 2026 IEEE 39th International Symposium on Computer-Based Medical Systems (CBMS), focusing on how Artificial Intelligence and Retrieval-Augmented Generation can support more equitable, reliable and patient-centred access to information in oncology.

The paper, entitled:

“Informed, Empowered, and Heard: AI and Retrieval-Augmented Generation as Tools for Equitable Patient Information in Oncology”

is authored by Lars Münter, Evangeli Bista, Maria Lavdaniti and Christos Frantzidis, with Evangeli Bista representing Kapa3 as Co-founder.

From access to information to meaningful patient empowerment

A cancer diagnosis creates an immediate need for information that is reliable, understandable and relevant to the individual patient.

At the same time, patients and their families are often expected to understand complex medical terminology, treatment options, prognosis discussions and administrative procedures at a moment of intense psychological and emotional pressure.

The paper highlights that acute stress associated with a serious diagnosis can affect working memory, attention and the ability to process new information. This means that patient information cannot be designed for an ideal, fully attentive reader; it must respond to the real cognitive and emotional conditions experienced by people facing cancer.

The key question is therefore not simply:

“How much information do we provide?”

but rather:

“Are we providing the right information, at the right time, in a form that people can understand and act upon?”

AI and Retrieval-Augmented Generation: towards trustworthy and evidence-grounded information

The publication places particular emphasis on Retrieval-Augmented Generation (RAG).

RAG architectures combine the generative capabilities of large language models with the retrieval of information from curated and verified knowledge sources. In a healthcare setting, this can include clinical guidelines, validated patient information resources, regulatory documents and peer-reviewed literature.

This approach offers an important advantage over purely generative AI systems: responses can be grounded in identifiable sources, supporting greater transparency and enabling patients and healthcare professionals to verify where information comes from.

In oncology, this is especially important.

A patient does not simply need a quick answer. They need information that is:

accurate, current, understandable, accessible and appropriate to their individual situation.

Artificial Intelligence as a tool for equity

One of the central themes of the paper is inequality in access to high-quality oncology information.

Geography, language, socioeconomic circumstances, health literacy, digital literacy and access to specialised healthcare services can significantly influence a person’s ability to understand their diagnosis, treatment options and rights.

The publication pays particular attention to the Greek context, where patients living in large urban centres may experience a very different information environment from those living in rural, remote or island communities.

When equity is treated as a core design principle, AI-RAG systems can potentially support:

  • multilingual access to health information,
  • different levels of language and information complexity,
  • voice-based interfaces,
  • shorter and more manageable units of information,
  • low-bandwidth or offline-capable solutions,
  • and opportunities for patients to return to information when they are ready to process it.

Technology alone, however, does not create equity.

The way technology is designed determines whether it reduces existing inequalities or reproduces them.

Designed with patients, for patient needs

The paper calls for an important shift in the way digital health systems are developed.

Many traditional health information systems are designed primarily around institutional or clinical workflows, with patient-facing communication added later.

For patient-centred AI, this logic must be reversed.

Systems should be designed with patients and around patient needs, with patients and informal carers actively involved in shaping the knowledge base, the questions the system is expected to answer and the ways information is presented.

This also means moving beyond systems that simply respond to individual questions.

A meaningful AI-supported information environment could help patients prepare for clinical consultations, organise their questions, understand the next steps in their care and become more aware of their rights.

The paper highlights applications such as consultation preparation guides, question prompts before appointments and post-consultation summaries as examples of how technology can support patients before, during and after important healthcare interactions.

AI should strengthen, not replace, human relationships

Perhaps the most important message of the publication is that the transformative potential of AI in oncology is not primarily technical. It is relational.

Artificial Intelligence should not create distance between patients and healthcare professionals.

It should help strengthen their communication.

A better-informed patient can arrive at a clinical consultation more prepared, identify questions and concerns more clearly, participate more actively in shared decision-making and communicate more effectively with the healthcare team.

The same applies to informal carers, who often carry a significant part of the informational and emotional burden of cancer care.

For this reason, the paper argues that AI-RAG systems should be designed to strengthen the relationship between patients, carers and healthcare professionals, rather than to replace any part of this human network of care.

For healthcare professionals, trustworthy information systems may also reduce the time required for basic information provision, allowing more of the clinical encounter to focus on nuanced discussions, decision-making and the human aspects of care that technology cannot replicate.

From information to trust

This scientific contribution adds to an increasingly important discussion about the future of healthcare:

How can Artificial Intelligence be developed and used in ways that genuinely respond to human needs?

The answer does not lie only in more powerful AI models or larger volumes of data.

It also lies in evidence, transparency, accessibility, co-design, equity and respect for patient rights.

As the paper concludes, people affected by cancer in Greece and across Europe deserve access to information that is accurate, personalised, accessible and respectful of their rights, regardless of where they live, the language they speak or the socioeconomic resources available to them.

For Kapa3, participating in this scientific discussion also reflects a broader commitment: ensuring that real patient needs, lived experience and equitable access are represented in the design and evaluation of the next generation of digital health and AI-supported tools.

Publication details

Title: Informed, Empowered, and Heard: AI and Retrieval-Augmented Generation as Tools for Equitable Patient Information in Oncology

Authors: Lars Münter, Evangeli Bista, Maria Lavdaniti, Christos Frantzidis

Published in: 2026 IEEE 39th International Symposium on Computer-Based Medical Systems (CBMS)

DOI: 10.1109/CBMS69103.2026.00302

find more 499901b523

The Value of Pause: Why We Need to “Disconnect” Even During Treatment

Summer is often associated with the idea of holidays. Images of the sea, travel, and carefree moments fill our daily lives, creating the impression that rest requires a suitcase, a destination, and distance from obligations.

However, for cancer patients who are undergoing treatment, recovering from surgery, or waiting for test results, holidays are often not possible. Medical appointments, treatments, side effects, physical fatigue, and uncertainty about one’s health can make travelling difficult or even impossible.

And yet, the need for rest does not diminish. On the contrary, it often becomes even more important.

Perhaps, then, it is worth redefining what a “holiday” means. Not as travelling somewhere else, but as the ability to pause, even briefly, the relentless cycle of stress, worry, and constant vigilance that often accompanies serious illness. It can be a reminder that life is not only about the disease.

Rest is not a luxury — it is a need

Recent scientific literature shows that people need periods of recovery in order to maintain psychological and physical balance. Recovery is not simply “resting”; it is a process through which the body reduces the physiological and psychological burden caused by chronic stress.

In psychology, the term psychological detachment is used to describe the mental ability to step away from sources of pressure. This means allowing oneself, even for a short while, not to think constantly about what feels overwhelming.

Research by Sonnentag, Binnewies, and Mojza (2010) showed that psychological detachment is associated with lower emotional exhaustion, better mood, and greater resilience in everyday life. Similarly, Fritz and colleagues (2010) found that people who are able to mentally disengage from stress experience higher levels of well-being, energy, and functioning.

Although these studies were mainly conducted among workers, the underlying mechanism applies to every person: when the brain remains in a constant state of alert, it struggles to recover its strength.

In this sense, these small pauses matter not because they make us “forget” the illness, but because they give the brain an opportunity to step out, even temporarily, of a continuous state of alarm.

When illness takes over every thought

The experience of cancer is not limited to treatment days. It often affects everyday life as a whole. Thoughts about tests, medical decisions, bodily changes, work, family, and the future may accompany a person from morning to night.

This constant mental vigilance is exhausting in itself.

International guidelines from the National Comprehensive Cancer Network (NCCN) recognise that psychological distress is a common part of the cancer experience and recommend integrating psychosocial support into overall patient care. Likewise, guidelines from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) emphasise that mental health care and quality of life are essential parts of cancer management.

Holidays are not always about travelling

It is easy to believe that rest requires a trip. Yet scientific research suggests that the greatest benefit of holidays does not necessarily come from the destination itself, but from a change of pace and temporary distance from stressors.

Nawijn and colleagues (2010) found that people tend to feel greater well-being shortly before and during holidays, but that this feeling often fades relatively soon after they return.

This finding reminds us of something important: psychological renewal does not depend only on a few days of holiday each year, but also on the small moments of relief that we can create in everyday life.

For someone undergoing treatment, these moments may be even more valuable.

What does it mean to “pause” as a cancer patient?

To pause does not mean ignoring reality or neglecting one’s health. It means allowing oneself to remember, even for a little while, that life is not only about illness.

This may include:

  • a few quiet minutes on the balcony or in the garden,
  • a short walk in nature, when possible,
  • listening to favourite music,
  • reading a book,
  • engaging in a creative activity,
  • spending time with people who make us feel safe,
  • a few minutes of relaxation or mindful breathing, when appropriate for one’s health condition.

These moments do not change the diagnosis. But they can change the experience of the day.

The importance of quality of life

In modern oncology, quality of life is now considered a key therapeutic goal. Treating the disease is not enough; it is equally important for the person to maintain as much functionality, autonomy, emotional balance, and sense of meaning as possible.

This importance is also reflected in the value framework for cancer treatments developed by the American Society of Clinical Oncology (ASCO). According to this framework, the value of a treatment is not determined solely by its effectiveness, but also by its toxicity, its impact on quality of life, and the personal priorities and preferences of the patient.

This highlights the importance of personalised, patient-centred care, in which the person’s everyday experience is an essential part of the therapeutic process.

Within this perspective, small moments of pause, the continuation of pleasant activities, and connection with what brings joy are not secondary aspects of life. They are meaningful elements that contribute to preserving quality of life. They are not luxuries, signs of weakness, or attempts to avoid reality. They are forms of self-care.

The same applies to family caregivers, who often experience high levels of emotional and physical burden. Taking some time for their own rest is not selfishness; it is a necessary condition for continuing to support their loved one in a meaningful way.

The value of a small pause

The experience of cancer often extends beyond the limits of the disease itself, affecting a person’s self-image, social roles, and daily life. Intense psychological distress and uncertainty can gradually allow the illness to occupy more and more space in life.

In this context, psycho-oncological education appears particularly important. Its aim is to help patients and family caregivers understand the emotional reactions that naturally accompany diagnosis and treatment, develop more effective coping strategies, and actively participate in treatment decisions.

In this way, the sense of control and self-efficacy is strengthened, while also preserving the sense that a person remains something more than their illness.

When health does not allow for travel, it is easy to feel deprived of something important. Yet perhaps the essence of a holiday lies not in the distance we travel, but in the distance we allow ourselves to take from stress.

To “pause” does not mean to stop being a patient. It means allowing oneself, even for a little while, to be something more than the illness.

Perhaps, in the end, the most meaningful holidays are not those that take us far from home, but those that allow us to rest the body, calm the mind, and turn toward ourselves with greater care.

A peaceful sunlit balcony with a chair, a book, a cup, flowers, and an olive tree, illustrating the importance of small moments of rest and self-care during cancer treatment.

By Marilia Barka
Psychology Student
Kapa3 Volunteer

DISABILITY CARD OR TRANSPORTATION PASS FOR PEOPLE WITH DISABILITIES 2026. WHAT BENEFICIARIES NEED TO KNOW.

The new explanatory circular regarding transportation for people with disabilities (PWDs) for 2026 has raised several questions among beneficiaries and their families who are trying to understand what the current rules are. The most common question is: “I have the plastic Disability Card. Do I also need to get a PWD Transportation Pass?”

The answer is that the Disability Card has not completely replaced the Transportation Pass. Both of these documents remain valid simultaneously, and the need for one or the
other depends on the mode of transportation used by each eligible person. To make this clearer, here’s what applies in each case.

Athens and Thessaloniki: The Disability Card can be used for urban travel

For travel on OASA transit in Athens and OSETH transit in Thessaloniki, the plastic Disability Card can be used by eligible beneficiaries.

Cardholders can travel by validating their card at the designated machines, without needing to obtain a
separate Travel Pass specifically for these transit services.

The following are required:

  • the Disability Card must be valid,
  • must bear the designated disability level II or III designation,
  • or the beneficiary must receive disability financial assistance from OPEKA,
  • and income criteria must be met where required.

URBAN KTEL BUSES IN THE PROVINCE: THE TRAVEL PASS REMAINS NECESSARY

This is the point that has caused the most confusion. Possession of a Disability Card does not mean that
the Travel Pass is no longer required for all trips.

For urban KTEL buses operated by the Regional Units, as well as by the municipalities of Kos and
Rhodes, a Mobility Card for People with Disabilities is required, even if the beneficiary holds a Disability Card.

Therefore, those who use urban KTEL buses in their area should apply:
– at the Citizen Service Centers (KEP),
– or at the relevant offices of the Regional Unit.

FOR 2026, THE PROCESS BEGINS ON JULY 1, 2026, AND ENDS ON NOVEMBER 30, 2026.
Intercity Buses (KTEL): 50% Discount on Fares

For travel on intercity buses (KTEL)—that is, for trips from one city to another—a 50% discount is available.
The discount can be obtained with:
– A valid Disability Card,
– or a Transportation Pass for People with Disabilities.

Thus, for intercity routes, the beneficiary has more options.

Are there income criteria for free transportation?

One point that often causes confusion concerns income. There are no income criteria for issuing the Disability Card.

The income limits apply to eligibility for free transportation.

For 2026, the limits are as follows:
– individual taxable income up to 23,000 euros,
– declared family income up to 29,000 euros.

The family income limit increases by 5,600 euros for each additional person with a disability of 67% or higher who lives with and is financially dependent on the taxpayer.

It is important to note that: OPEKA disability benefits are not included in the above income limits. A relevant certificate from OPEKA may be required to exclude them.

Who is exempt from the income criteria?

People who are totally blind are exempt from the income criteria.

What applies to the companion?

In many cases, a companion is also entitled to travel.
If the Disability Card is marked with an “S” (Companion):

in Athens and Thessaloniki, the companion travels with the cardholder upon a single validation of the card. For KTEL buses, however, the prescribed procedure and the corresponding Companion Travel Pass are required where necessary.

So, what do beneficiaries need to keep?

The Disability Card is a significant benefit, but it does not mean that the Travel Pass is being
eliminated.
In simple terms:
Disability Card:
✔ Athens and Thessaloniki
✔ Intercity KTEL buses for a 50% discount
Travel Pass:
✔ Provincial KTEL buses
✔ Situations where a companion’s entitlement is required
✔ Those who do not have a Disability Card

At Kapa3, we believe that accurate information can save time, trips, and unnecessary hassle,
especially for people who already face increased challenges due to a disability or a serious illness.

View the circular here: TRANSPORTATION 2026
DISABILITY CIRCULAR

For more information, please don’t hesitate to contact the Kapa3 team:

📍Athens: 13 Kosti Palama, 3rd floor, (9:00 AM – 5:00 PM)
📍13 Kosti Palama, 11141 Athens
☎️210 5221424
📱6906265170
www.kapa3.gr, info@kapa3.gr

The Right to Be Forgotten: A New Era of Dignity for Cancer Survivors

Life after cancer should not be accompanied by lifelong financial exclusion

For many decades, completing cancer treatment did not always mean the end of obstacles for those who had been diagnosed with the disease. Years after their treatment, many survivors continued to face higher insurance premiums, denied insurance applications, and difficulties accessing financial services.A history of cancer could act as a permanent “stigma,” even many years after treatment had ended.

Thus, medical progress and a return to daily life were not always accompanied by corresponding social and economic rehabilitation.

With Law No. 5317/2026, published on July 10, 2026, Greece is moving forward with the legislative enshrinement of the so-called “Right to Be Forgotten” for cancer survivors, in the context of insurance contracts linked to consumer credit agreements. This specific provision is found in Article 16, paragraph 4, of the law.

What the new provision stipulates

The law prohibits the use of personal data related to a consumer’s cancer diagnosis when such data is to be used for an insurance contract linked to a credit agreement and five years have passed since the completion of treatment.

Simply put, once the five-year period has elapsed, a prior history of a cancer diagnosis cannot be used in this specific context as a factor in assessing the insurance contract accompanying the credit agreement. This represents a significant shift: individuals are no longer assessed indefinitely through the lens of a past
illness, but are given the opportunity to move forward with their lives without their previous diagnosis serving as a permanent obstacle.

The four key points of the new entitlement

The Right to be Forgotten does not mean that the diagnosis is deleted from the medical record. It means that, after the prescribed five-year period, data related to the cancer diagnosis may not be used for that specific insurance purpose.

Fourth, special oversight is provided for.

The Personal Data Protection Authority is responsible for enforcing paragraph 4 of Article 16 and possesses the supervisory and auditing powers provided for by the General Data Protection Regulation.

What the New Regulation Does Not Cover

Accurate information is particularly important so that citizens are aware of both their rights and the actual
limits of the protection provided.

The new legislative provision:

  • does not apply to all forms of private insurance,
  • does not automatically guarantee the approval of a loan or an insurance application,
  • does not cover credit agreements secured by a mortgage on real property,
  • does not cover credit intended for the purchase or retention of rights in real estate,

does not cover professional or business loans, as the law applies to consumers acting outside the
scope of their professional or business activities.

Furthermore, consumer credit agreements already in effect as of November 20, 2026, will, as a general rule, continue to be governed by the previous legal framework until their expiration.
Therefore, the new regulation represents a very important step, but it does not yet provide comprehensive coverage of all the financial and insurance needs of survivors.

From Voluntary Commitment to Legal Enshrinement

The Right to Be Forgotten did not first appear in Greece in 2026. As of March 26, 2024, the Code of Ethics of the Hellenic Association of Insurance Companies has been in effect, to which life insurance companies had adhered.

The Code applied to life insurance policies linked to mortgage, business, or consumer loans, with a maximum total insured amount of 300,000 euros. It provided for a ten-year period following the completion of treatment for those diagnosed as adults and a five-year period for those diagnosed before
turning 18.

The new legislation is particularly significant because protection is no longer based exclusively on the insurance industry’s voluntary commitment. For contracts falling within its scope, the failure to use the oncological diagnosis after the five-year period becomes a legal obligation.

At the same time, there is a need to clarify the relationship between the new law and the existing Code, particularly with regard to mortgage and business loans that are not subject to the new legislative provision.

Additional Safeguards for Consumers

Article 16 includes other important safeguards. When insurance is required for the granting of credit, the creditor must accept equivalent insurance coverage from an insurance company of the consumer’s choice. Choosing a different company must not result in less favorable credit terms.

At the same time, the consumer is given a period of at least three business days to compare insurance quotes, unless the consumer requests in writing that the contract be concluded earlier.

The European Dimension

The Greek regulation transposes Directive (EU) 2023/2225 on consumer credit agreements. The European
Directive requires Member States to establish a time limit beyond which data related to oncological
diagnoses may not be used for insurance policies linked to credit agreements. The European text stipulated that this period must not exceed fifteen years; Greece opted for the significantly shorter period of five years.

This choice has particular social significance. It recognizes that advances in oncology, increased survival rates, and people’s return to family, social, and professional life must be accompanied by corresponding
developments in the law.

When Does It Take Ef ect?

Although Law No. 5317/2026 has already been published, the provisions of Part A, which include the
Right to Be Forgotten, will take effect on November 20, 2026.
Until then, substantial preparation is required on the part of banks, insurance companies, and the relevant
authorities. Clear procedures, understandable information for citizens, appropriate staff training, and an
easily accessible mechanism for submitting reports or complaints are needed.

A Significant Achievement—Not the End of the Journey

The Right to Be Forgotten represents a significant institutional victory for dignity and equality. Cancer
should not be a lifelong social and economic stigma. A person’s medical history should not negate their
right to plan for the future, participate equally in society, and make a fresh start.
At the same time, the new regulation must be viewed as a starting point, not the culmination of our
efforts. The next step must be to extend meaningful protection to more insurance and financial products,
including housing needs, as well as to address the discrimination that continues to occur in the workplace
and other aspects of social life.
Scientific progress has transformed cancer from a terminal diagnosis into an experience of life and
survival for millions of people. Society and the law must follow suit.

Because the Right to Be Forgotten is not a privilege. It is every person’s right not to remain forever
trapped by a past diagnosis—and to move forward into the future without discrimination, without
stigma, and with dignity.

Find more : http://elib.aade.gr/elib/view?

The Active Role of Patient Organizations in Shaping Public Policy: How Our Health Advocacy Ef orts Are Put into Action

At the Cancer Patient Guidance Center, we believe that the voices of patients, their families, and the organizations that represent them must be heard loud and clear where decisions are made.

Improving the quality of life for cancer patients, ensuring access to new treatments, and meeting the needs of caregivers are not just requests but rights that are asserted through organized advocacy. To make this a reality, the right tools are needed.

The new “Guide to Mapping Public Consultation Tools”

As part of the “ENERGO – Toward an Open State” project, HIGGS has created a practical guide that maps the available mechanisms for participation at the local, national, and European levels.

This guide serves as a roadmap for Civil Society Organizations (CSOs), providing a detailed overview of:
• How institutional consultation tools function
• The opportunities for organizations to actively participate in policy-making
• The requirements for accessing these mechanisms
• The challenges and limitations, so that our interventions are well-informed and effective

Why might this be of interest to the beneficiaries of our Center?

Participation in shaping public policy is not an abstract concept. In cancer care, it translates into very specific changes:
1. Equal access to care: advocating for better infrastructure, shorter wait times, and free access to innovative medications.
2. Support for caregivers: establishing leave policies, benefits, and support systems for the people who stand by their side
3. Rights in the workplace: protecting cancer patients from discrimination in the workplace during and after treatment.

Summary & Structure of the Public Consultation Tools Guide

The “Public Consultation Tools Guide” was developed as part of the project “ENERGO – Toward an Open State” (implemented by HIGGS and co-funded by the European Union, the Bodossaki Foundation, and the NGO Support Centre). It is a practical reference tool designed to empower civil society organizations (CSOs) by strengthening their capacity for meaningful, evidence-based participation in public policy-making and strategic advocacy.

The guide is organized into the following sections:

1. Introduction & Institutional Landscape: This section presents the framework for the guide’s development, which was based on research and experiential tools involving dozens of civil society organizations. It analyzes the challenges of the institutional landscape, noting that the main obstacle for organizations is not the absence of tools, but rather the fragmentation, lack of visibility, and complexity of existing mechanisms,

2. National Tools for Public Consultation & Participation: maps and presents in detail the tools available in Greece, such as OpenGov, the KEDE & LocalWatch consultation platform, Vouliwatch, the YPEN Participation Platform, the National Register of Procedures (“Mitos”), Open Council & Crowd Participation, as well as Diafania & POTHEN.

3. European Public Consultation & Participation Tools: presents mechanisms for engagement at the European Union level, such as Have Your Say, the European Citizens’ Initiative (ECI), Consul Democracy, Loomio & Decidim, and others.

4. Tool Selection Guide & Conclusions: Provides consistent evaluation criteria (purpose, implementing body, prerequisites, limitations) so that each organization can select the most appropriate tool based on the objective of its engagement.

About the “ENERGO” Project & the PLATO Program

The “ENERGO: Toward an Open State – Participation, Advocacy, and Empowerment of Civil
Society Organizations” project is being implemented as part of the PLATO program, with HIGGS serving as the implementing partner. The PLATO program (“Protecting democracy, human rights, and the rule of law through an open civic space”) aims to strengthen the fundamental rights and values of the EU in both Greece and Cyprus. It is co-funded by the European Union through the Citizens, Equality, Rights and Values (CERV) program, the Bodossaki Foundation, and the NGO Support Center. The Bodossaki
Foundation serves as the coordinator in partnership with the NGO Support Center.

View and download the guiderZT9sW-Οδηγός Εργαλείων Δημόσιας Διαβούλευσης.

 

Memorandum of Understanding between the University of West Attica—specifically the Department of Occupational Therapy—and the NGO KAPA3.

On Tuesday, June 9, a meeting was held to sign a Memorandum of Understanding between the University of West Attica—specifically the Department of Occupational Therapy—and the NGO KAPA3.

The meeting was attended by the Rector of the University of West Attica, Panagiotis Kaldis Penelope Vlotinou, Assistant Professor in the Department of Occupational Therapy Evangelia Bista, co-founder of the organization, as well as representatives from both organizations, including the interdisciplinary team of KAPA3: Despoina Chrysostomou, Psychologist Katerina Georgiopoulou, Social Worker Yiannis Kontogiorgis, Psychologist, and Eleftheria-Irini Polyzoti, an intern from the Department of Social and Educational Policy, as well as students from the Occupational Therapy Department.

During the meeting, a constructive discussion took place regarding the prospects for cooperation between the two organizations, with the aim of developing joint actions and initiatives that will contribute to strengthening education, research, social contribution, and the connection between the academic community and society.

In this context,  it was decided in April to jointly organize a major scientific conference, which will focus on an interdisciplinary and holistic approach to health, on combating social inequalities in healthcare, as well as on the management of chronic disease. The aim of this initiative is to raise community awareness, facilitate the exchange of expertise among professionals and scientific bodies, and disseminate scientific knowledge and information to the general public.

Special mention was made of the innovative work of KAPA3, the digital Health Navigator “Myrto,” a modern artificial intelligence tool currently under development and designed to support cancer patients, their families, and their caregivers. “Myrto” will function as a digital assistant (Chatbot) and Health and Rights Navigator, providing immediate, reliable, and personalized information on health, social welfare, rights, benefits, and available support services. The project aims to empower patients, improve their access to information, and reduce inequalities in health and social care through the use of digital technologies and artificial intelligence applications. The development of “Myrtos” represents a pioneering application of social artificial intelligence in the field of oncology care in Greece and is part of KAPA3’s strategy to promote innovation, accessibility, and the active participation of patients in managing their own health.

The meeting concluded in a particularly positive atmosphere of mutual appreciation and recognition. In this context, the Department of Occupational Therapy at the University of West Attica made a symbolic gesture toward the representative of KAPA3, Evangelia Bista, presenting her with a commemorative gift as a token of appreciation for her many years of valuable social contribution in the field of support for cancer patients. At the same time, as a gesture of hospitality and appreciation, the team was offered a specially produced wine, which is an original creation of the University of West Attica.